- Home
- OCS
as 10-17-2025 3:59pm EST
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
| Founded: | 2003 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 869.8M | IPO Year: | N/A |
| Target Price: | $41.00 | AVG Volume (30 days): | 77.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.00 - $23.08 | Next Earning Date: | 11-06-2025 |
| Revenue: | $960,668 | Revenue Growth: | -12.29% |
| Revenue Growth (this year): | 36.75% | Revenue Growth (next year): | 1261.53% |
Latest Oculis Holding AG Ordinary shares News
OCS Breaking Stock News: Dive into OCS Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
GlobeNewswire
5 days ago
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
Zacks
9 days ago
Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock?
Simply Wall St.
10 days ago
Oculis Holding (NasdaqGM:OCS) Valuation Spotlight as Privosegtor Advances Toward Pivotal Neuroprotection Trials
GlobeNewswire
10 days ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
MT Newswires
13 days ago
Oculis to Advance Privosegtor to Registrational Trials for Neuro-Ophthalmology Indications
GlobeNewswire
13 days ago
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
Zacks
a month ago
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?
Compare OCS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCS Oculis Holding AG Ordinary shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.